

DAFTAR PUSTAKA

1. Alakija KS, Fadeyi A, Ogunmodede JA, Desalu O. Factors influencing adherence to antiretroviral medication in Ilorin, Nigeria. *J Int Assoc Physicians AIDS Care (Chic)*. 2010;9(3):191-5.
2. Carter M. Information series for HIV-positive people HIV & children. Lithosphere. 2nd ed. London: NAM;2005.p.1-36.
3. Galistiani GF, Mulyaningsih L. Kepatuhan pengobatan antiretroviral pasien HIV/AIDS Di RSUD Prof. Dr. Margono Soekarjo Purwokerto. *Media Farm*. 2013;10(2):94-103.
4. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. *Medicine (Baltimore)*. 2016;95(15):e3361.
5. Sari NH. Hubungan tingkat kepatuhan konsumsi obat antiretroviral (ARV) pada pasien HIV dengan kejadian infeksi protozoa usus di RSUP.Dr.M.Djamil Padang (skripsi). Program Studi Strata I Jurusan Pendidikan Dokter Fakultas Kedokteran. Kota Padang: Universitas Andalas;2017. p. 40.
6. Ganasegaran S. Hubungan tingkat kepatuhan mengonsumsi antiretroviral terhadap perbaikan respons imun pasien HIV-1 di RSUP. Dr. M. Djamil Padang (skripsi). Program Strata I Jurusan Pendidikan Dokter Fakultas Kedokteran. Kota Padang: Universitas Andalas;2018.
7. Shukla M, Agarwal M, Singh VK. Nonadherence to antiretroviral therapy among people living with HIV/AIDS attending two tertiary care hospitals in district of Northern India. *Indian J Community Med*.2016; 41(1):55-61.
8. Sangeda RZ, Mosha F, Vandamme AM. Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. *Drug Healthc Patient Saf*. 2018; 10:79-88.
9. Kliegman RM, Geme JS, editors. Nelson textbook of pediatrics. 21th ed. New York: Elsevier;2019.
10. Tille PM. Bailey & scott's diagnostic microbiology. 13th edition. New York: Elsevier;2014.
11. Widoyono. Penyakit tropis epidemiologi, penularan, pencegahan dan pemberantasannya. 2nd ed. Jakarta: Erlangga Medical series;2011.

12. UNAIDS(2019a). Global HIV statistics: United Nation programme on HIV and AIDS. <https://www.unaids.org/en/resources/facts-sheet>. -Diakses Februari 2020.
13. UNAIDS (2019b). Communities at the centre the response to HIV in Asia and the Pacific: United Nation programme on HIV and AIDS. https://www.unaids.org/sites/default/files/media_asset/2019-global-AIDS-update-asia-pacific-en.pdf - Diakses Februari 2020.
14. Kemenkes (2019). Laporan perkembangan HIV AIDS & penyakit infeksi menular seksual (PIMS) triwulan II tahun 2019. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pencegahan dan Pengendalian Penyakit. https://www.sihadeptes.go.id/portal/files_upload/Laporan_HIV_TW_II_20192.pdf - Diakses Februari 2020.
15. Hardisman, Firdawati, Sulreni IN. Model determinan perilaku “Lelaki Seks Lelaki” di Kota Padang, Sumatera Barat. *Jurnal Kesehatan Andalas*. 2018;7(3):306.
16. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. *Annu Rev Pathol*. 2011;6:223-48.
17. WHO (2007). HIV/AIDS programme strengthening health services to fight HIV/AIDS, WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization. <https://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf> - Diakses Januari 2020.
18. Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. *Cureus*. 2016 Mar;8(3): e515.
19. Fairall LR, Bachmann MO, Louwagie GMC, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in South African program – a cohort study. *Arch Intern Med*. 2008;168(1):86-93.
20. Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group: Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Eng J Med*. 2015;373(9):795-807.

21. Kementerian Kesehatan Republik Indonesia. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral pada orang dewasa. http://angsamerah.com/pdf/Angsamerah-Pedoman_Nasional_ART_2011.pdf - Diakses Januari 2020.
22. Clavel F, Hance AJ. HIV drug resistance. *N Engl J Med*. 2004;350:1023-35.
23. Brenner B, Turner D, Oliveira M, et al. A V10M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. *AIDS*. 2003;17:F1-F5.
24. Zdanowicz MM. The pharmacology of HIV drug resistance. *Am J Pharm Educ*. 2006;70(5):100.
25. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med*. 2011;1:a006841.
26. Faria NR, Rambant A, Suchard MA, Baele G, Bedford T, Ward MJ, et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. *Science*. 2014;346:56-61.
27. Nasronudin, editors. *HIV&AIDS pendekatan biologi molekuler, klinis dan sosial*. Surabaya: Airlangga University Press;2007. p.1-309.
28. Subowo. *Imunologi klinik*. Jakarta: Sagung Seto;2013.p. 175-209.
29. Sharp PM, Hahn BH. Origins of HIV and the AIDS Pandemic. *Cold Spring Harb Perspect Med*. 2011;1(1):a006841
30. Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, editor. *Virology*. 3rd ed. Philadelphia: Lippincott-Raven;1996. p. 1881-1952.
31. Sharp PM, Hahn HB. The evolution of HIV-1 and the origin of AIDS. *Philos Trans R Soc Lond B Biol Sci*. 2010;365(1552): 2487-2494.
32. Jeba Keni. Describe the structure of HIV with diagram. 15 Oktober 2019. <https://www.toppr.com/ask/question/describe-the-structure-of-hiv-with-diagram/>. – Diakses Mei 2020.
33. Onyancha B. An Informetric investigation of the relatedness of opportunistic infections to HIV/AIDS. *Information Processing and Management*. 2005;41(1):1573-88.

34. Becerra JC, Bildstein LS, Gach JS. Recent insights into the HIV/AIDS Pandemic. *Microb Cell*. 2016 Sep 05;3(9):451-475.
35. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. *Science*. 2005;308:1582–83.
36. Waymack JR, Sundareshan V. Acquired Immune Deficiency Syndrome (AIDS). StatPearls Publishing LLC. <https://www.ncbi.nlm.gov/books/NBK537293/>. Diakses Maret 2020.
37. Shaw GM, Hunter E. HIV transmission. *Cold Spring Harb Perspect Med*. 2012 Nov; 2(11):a006965.
38. Murray, PR. Basic medical microbiology. Philadelphia: Elsevier;2018. P.99-102.
39. Jenness SM, Neaigus A, Hagan H, Murrill CS, Wendel T. Heterosexual HIV and sexual partnerships between injection drug users and noninjection drug users. *AIDS Patient Care STDS*. 2010;24(3):175–181.
40. Granich R, Gupta S, Hersh B, et al. Trends in AIDS deaths, new infections and ART coverage in the top 30 countries with the highest AIDS mortality burden; 1990–2013. *Plos One*. 2015;10(7): e0131353.
41. Buchbinder SP. HIV epidemiology and breakthroughs in prevention 30 years into the AIDS epidemic. *Top Antivir Med*. 2011;19(2):38.
42. Chadburn A, Abdul-Nabi AM, Teruya BS, Lo AA. Lymphoid proliferations associated with human immunodeficiency virus infection. *Arch Pathol Lab Med*. 2013; 137(3):360-70.
43. Ersha RF, Ahmad A. Human immunodeficiency virus - Acquired immunodeficiency syndrome dengan sarkoma kaposi. *Jurnal Kesehatan Andalas*. 2018;7(3):131-4.
44. German Advisory Committee Blood (Arbeitskreis Blut). Human immunodeficiency virus (HIV). *Transfus Med Hemother*. 2016 May; 43(3): 203–222.
45. Demirkhanyan L, Marin M, Lu W, Melikyan GB. Sub-inhibitory concentrations of human α -defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. *PLoS Pathog*. 2013;9:e1003431.

46. Pauls E, Jiminez E, Ruiz A, Permanyer M, Ballana E, Costa H, et al. Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-19 through the upregulation of SAMHD1. *J Immunol*. 2013;190:4736–4741.
47. Naif HM. Pathogenesis of HIV infection. *Infect Dis Rep*. 2013 Jun 6;5(Suppl 1): e6.
48. Richman DD. Normal physiology and HIV pathophysiology of human T-cell dynamics. *J Clin Invest*. 2000 Mar 1; 105(5): 565–566.
49. Romo FT, Gillani FS, Ackerman P, Rana A, Kojic EM, Beckwith CG. Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. *R I Med J* (2013), 2015; 98(1): 26–30.
50. Aru W. Sudoyo. *Buku ajar ilmu penyakit dalam, jilid II*. 6th ed. Jakarta: Interna Publishing; 2014.
51. WHO (2005). Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. World Health Organization African Region. <https://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf> - Diakses pada Mei 2020.
52. Peraturan Menteri Kesehatan Republik Indonesia nomor 87 tahun 2014 tentang pedoman pengobatan antiretroviral. <http://preventcrypto.org/wp-content/uploads/2015/10/IndonesiaAdultARTguidelines20141432907982.pdf>. - Diakses pada April 2020.
53. Vajpayee M, Kaushik S, Seth P. CDC staging based on absolute CD4 count and CD4 percentage in an HIV-1-infected Indian population: treatment implications. *Clin Exp Immunol*. 2005;141(3):485-490.
54. Zulfiqar HF, Javed A, Sumbal, Afroze B, Ali Q, Akbar K. HIV diagnosis and treatment through advanced technologies. *Front Public Health*. 2017;5:32.
55. Eggleton JS, Nagalli S. Highly active antiretroviral therapy (HAART). StatPearls Publishing LLC. <https://www.ncbi.nlm.nih.gov/books/NBK554533/>.
56. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA*. 2012 Jul 25;308(4):387-402.

57. Tjokroprawiro A. Buku ajar ilmu penyakit dalam. 2nd ed. Surabaya: Airlangga University Press; 2015.
58. Dybul M, Fauci AS, Barlett JG, Kaplan JE, Pau AK, et al. Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of panel on clinical practices for treatment of HIV. *Ann Intern Med.* 2002;137(5Pt 2):381-433.
59. Aboulker J, Swart A. Preliminary analysis of the CONCORDE trial. *Lancet.* 1993;341(8849):889-890.
60. Gunthard HF, Aberg JA, Eron JJ, International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA.* 2014;312(4):410-425.
61. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral Society-USA Panel. *JAMA.* 2018;320(4):379-396.
62. Lennox JL, Landovitz RJ, Ribaldo HJ, Ofotokun I, Na LH, Godfrey C, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med.* 2014;161(7):461-71.
63. Schaffer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. *Ann Pharmacother.* 2010.;4(1):145-56.
64. Miao M, De Clerq E, Li G. Clinical significance of chemokine receptor antagonists. *Expert Opin Drug Metab Toxicol.* 2020;16(1):11-30.
65. Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. *AIDS Educ Prev.* 2014;26(6):521-37.
66. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. *BMC Public Health Open Access.* 2018 (18):825.

67. Liu Y, Lu N, Wang M, Chen X, Xiao S, Luo D. Suicidal behaviors among newly diagnosed people living with HIV in Changsha, China. *AIDS Care*. 2017;29(5):1-5.
68. Wanchu A, Kaur R, Bambery P, Singh S. Adherence to generic reverse transcriptase inhibitor-based antiretroviral medication at a Tertiary Center in North India. *AIDS Behav*. 2007;11:99-102.
69. Mahardining AB. Hubungan antara pengetahuan, motivasi dan dukungan keluarga dengan kepatuhan terapi ARV ODHA. *Jurnal Kesehatan Masyarakat*. 2010; 5(10):131-137.
70. Umayyah F. Hubungan anatara dukungan keluarga sebagai PMO dengan kepatuhan berobat penderita di BP4, Klaten (Skripsi). Kota Jogjakarta: Universitas Gajah Mada;2008.
71. Basti DB, Mahesh V, Geeta V. Factors affecting antiretroviral treatment adherence among people living with human immunodeficiency virus/acquired immunodeficiency syndrome: A prospective study. *J Family Med Prim Care*. 2017.6(3):482-486.
72. Martin F, Lee J, Thomson E, Tarrant N, Hale A, Lacey CJ. Two cases of possible transmitted drug-resistant HIV; likely HIV superinfection and unmasking of pre-existing resistance. *Int J STD AIDS*. 2016;27(1):66-9.
73. Ghanbari A, Khiaban MO, Aslani A, Faraji AR, Mohammadi M, Kazemi AF. Assesment of adherence to therapy and exploring of barriers and facilitators in HIV positive patients in Tabriz-Iran: a mixed method study protocol. *Reprod Health*. 2019(16);108.
74. Riani DA, Ikawati Z, Kristina SA. Validasi 8-item Morisky Medication Scale versi Indonesia pada pasien hipertensi dewasa di puskesmas kabupaten Sleman dan kota Yogyakarta (thesis). Program Strata II Jurusan Ilmu Farmasi. Universitas Gajah Mada. 2017.
75. Zongo A, Guenette L, Gregoire JP. Revising the internal consistency and factorial validity of the 8-item Morisky Medication Adherence Scale. *SAGE Open Med*. 2016;(4):2050312116674850.

76. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. *The Journal of Clinical Hypertension*. 2008;10:348-354.
77. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Medical Care*. 1986;24:67-74.
78. Tasyriqiyah MIH. Gambaran Fungsi Keluarga Pada Pasien HIV/AIDS di RSUP Dr. M. Djamil Padang (skripsi). Program Studi Strata I Jurusan Pendidikan Dokter Fakultas Kedokteran. Kota Padang: Universitas Andalas;2019. p. 32.
79. Doris M, Janet S, Faith M, Achilles K. Perceptions of quality of life among Uganda patients living with HIV: a qualitative study. *BMC Public Health*. 2014. 14:343.
80. Perkembangan beberapa indikator utama sosial-ekonomi Indonesia. Badan Pusat Statistik Indonesia; Agustus 2018. <https://www.bps.go.id>. -Diakses pada tanggal 3 Mei 2020.
81. Presentase penduduk miskin September 2019 turun menjadi 9,22%. Badan Pusat Statistik Indonesia; Jadwal rilis Januari 2020. <https://www.bps.go.id/pressrelease/2020/01/15/1743/presentase-penduduk-miskin-september-2019-turun-menjadi-9-22-persen.html>. - Diakses pada Mei 2020.
82. Suryana K, Suharsono H, Antara IG PJ. Factors associated with adherence to anti-retroviral therapy among people living with HIV/AIDS at Wangaya Hospital In Denpasar, Bali, Indonesia: A Cross-Sectional Study. *HIV AIDS (Auckl)*. 2019;11:307-312.
83. UNAIDS (2020). UNAIDS data 2020. <https://www.unaids.org/en/resources/documents/2020/unaid-data.pdf>-Diakses Desember 2020.
84. WHO (2020). Latest HIV estimates and update on HIV policies uptake, July 2020. <https://www.who.int/docs/default-source/hiv-hq/presentation-international-aids-conference-2020.pdf>
85. Khairunnisa, Sawaraswati LD, Adi MS, Udiono A. Gambaran kepatuhan pengobatan ARV (Antiretroviral) (Studi pada wanita pekerja seks (WPS) positif HIV/AIDS di Kabupaten Batang). *JKM*. 2017; 5(4): 2356-3346.

86. Li L, Lee SJ, Wen Y, Lin C, Wan D, Jiraphongsa C. Antiretroviral therapy adherence among patients living with HIV/AIDS in Thailand. *Nurs Health Science*. 2010;12(2): 212-220.
87. Murphy DA, Johnston RK, Martin D, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV –infected adults. *AIDS Patient Care STDs*. 200;14:47-58.
88. Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009-2016: a nationwide study. *Sci Rep*. 2018;8:3133.
89. Kheswa JG. Non-adherence to antiretroviral treatment by people living with HIV/AIDS in black communities in South Africa: sociocultural challenges. *Mediterr J Soc Sci*. 2014;5(14):450-457.
90. Kalichman SC, Cherry C, Kalichman MO. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. *AIDS Patient Care STDs*. 2010 May; 24(5):271-277.

